Media
Focus on the development of new antibody drugs for the treatment of tumors and autoimmune inflammatory diseases

Media

新闻动态
Homepage
/
News

China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
READ MORE
20
2020-08

Jun.19th, 2020 HJB and Kanova Biopharma reached strategic collaboration

Time : 2020-08--20 Click volume : 0
Jun.19th, 2020 HJB and Kanova Biopharma reached strategic collaboration
查看详情 查看详情
19
2019-02

Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

Time : 2019-02--19 Click volume : 0
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
查看详情 查看详情
08
2020-01

Nov.26th, 2018 Kanova had obtained A round of financing with 115 million yuan (RMB)

Time : 2020-01--08 Click volume : 0
Nov.26th, 2018 Kanova had obtained A round of financing with 115 million yuan (RMB)
查看详情 查看详情
Previous page
1
这是描述信息

Add

Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,

Haidian District, Beijing City, China, 10084

A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123

COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd   苏ICP备19068714号-1   Power by 300.cn Beijing

这是描述信息

Follow us